4.7 Article

Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association

期刊

DIABETES CARE
卷 45, 期 7, 页码 1670-1690

出版社

AMER DIABETES ASSOC
DOI: 10.2337/dci22-0014

关键词

-

资金

  1. AstraZeneca
  2. Innolife
  3. Applied Therapeutics
  4. Roche Diagnostics
  5. Abbott Diagnostics
  6. Cleveland Clinic
  7. Boehringer Ingelheim/Lilly
  8. Merck
  9. Roche
  10. Sanofi/Lexicon
  11. American Heart Association
  12. Novo Nordisk
  13. Dexcom
  14. Apple
  15. Twine Consulting
  16. Blue Cross Blue Shield

向作者/读者索取更多资源

Heart failure is a common complication of diabetes, even in the absence of other cardiovascular diseases. With the increasing prevalence of diabetes globally, particularly type 2 diabetes, the burden of heart failure on the healthcare system is expected to rise. This consensus report aims to provide clear guidance to practitioners on screening and diagnosing heart failure in individuals with diabetes.
Heart failure (HF) has been recognized as a common complication of diabetes, with a prevalence of up to 22% in individuals with diabetes and increasing incidence rates. Data also suggest that HF may develop in individuals with diabetes even in the absence of hypertension, coronary heart disease, or valvular heart disease and, as such, represents a major cardiovascular complication in this vulnerable population; HF may also be the first presentation of cardiovascular disease in many individuals with diabetes. Given that during the past decade, the prevalence of diabetes (particularly type 2 diabetes) has risen by 30% globally (with prevalence expected to increase further), the burden of HF on the health care system will continue to rise. The scope of this American Diabetes Association consensus report with designated representation from the American College of Cardiology is to provide clear guidance to practitioners on the best approaches for screening and diagnosing HF in individuals with diabetes or prediabetes, with the goal to ensure access to optimal, evidence-based management for all and to mitigate the risks of serious complications, leveraging prior policy statements by the American College of Cardiology and American Heart Association.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据